ClinicalTrials.gg
CompletedNCT03208933Updated Nov 20, 2020Results posted

Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).

A Phase 3 interventional study of Pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Hoffmann-La Roche. Completed at 11 sites in Russian Federation. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-20.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Enrollment
14th of 21
60 · median 89
Started
2017
the only one that year
Phase 3
6 of 21
1 open now
Registered
12th of 21
by date
Lead sponsor
4 of 21
Hoffmann-La Roche

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 14th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 12th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

This study is a national, multicenter, interventional, non-randomized, non-controlled, open-label study to assess the effectiveness of pirfenidone in participants with IPF in Russian clinical practice.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Pirfenidone, UIP, IPF, FVC
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical symptoms consistent with IPF of ≥ 6months duration
  • Participants could have both "confident" or "consistent" with UIP diagnosis of IPF based on clinical, radiologic and pathologic data according to 2011 American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines at the Screening. HRCT scan performed within 24 months before the start of the Screening may be used, if it meets all image acquisition guideline
  • No features supporting an alternative diagnosis on transbronchial , bronchoalveolar lavage (BAL), or surgical lung biopsy, if performed. Results of the surgical lung biopsy performed within the last 4 years must be confirmed by central review
  • Participants with %FVC ≥ 40 % at the Screening
  • Participants with %Carbon monoxide diffusing capacity (DLCO) ≥ 30 % at the Screening
  • Ability to walk ≥ 100 m during the 6-minute walk test at the Screening
  • Eligible participants must discontinue all prohibited medications at least 28 days before the Screening
  • Female participants of must have negative urine pregnancy test at the Screening and before first dosing on Day 1

Exclusion criteria

Exclusion Criteria:

  • Significant clinical worsening of IPF between Screening and Day 1, in the opinion of the investigator
  • Relevant airways obstruction (i.e. pre-bronchodilator forced expiratory volume (FEV)1/FVC \< 0.7)
  • Cigarette smoking within 28 days before the start of treatment or unwilling to avoid tobacco products throughout the study
  • History of environmental exposure known to cause pulmonary fibrosis (PF), including but not limited to drugs (such as amiodarone), asbestos, beryllium, radiation, and domestic birds
  • Known explanation for interstitial lung disease, including but not limited to radiation, drug toxicity, sarcoidosis, pneumonitis, bronchiolitis obliterans organizing pneumonia, (HIV), viral hepatitis, and cancer
  • Clinical diagnosis of any connective tissue disease, including but not limited to scleroderma, polymyositis/ dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis
  • During baseline analysis of HRCT, significant coexistent emphysema (emphysema extent greater than extent of fibrosis) confirmed by central review
  • Planned lung transplantation during the study
  • Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis
  • Unable to perform 6MWT or to undergo pulmonary function test
  • Any history of likely to result in significant disability or likely to require significant medical or surgical intervention within the next 1 years. This does not include minor surgical procedures for localized cancer (e.g., basal cell carcinoma)
  • History of severe hepatic impairment or end-stage liver disease
  • History of end-stage renal disease requiring dialysis
  • History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months
  • Pregnancy or lactation, or intention to become pregnant during the study. Women of childbearing capacity are required to have a negative urine pregnancy test before treatment and must agree to maintain highly effective
  • Liver function test outside specified limits at the Screening: total above the (ULN); aspartate or (AST or ALT) > 3 × ULN; alkaline phosphatase > 2.5 × ULN
  • \< 30 mL/min, calculated using the Cockcroft-Gault formula
  • (ECG) with a corrected according to Fridericia's formula (QTcF) > 500 msec at the Screening
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Pirfenidone

    Participants will be administered pirfenidone 2403 milligram per day (mg/d) orally for 26 weeks in participants with IPF.

    Drug: Pirfenidone

Interventions

  • Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.

    Also known as: Esbriet, RO0220912

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 26 in Absolute Millilitre (mL) Forced Vital Capacity (FVC)

    FVC is a standard pulmonary function test. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Baseline FVC will be the average of the highest FVC measurement recorded at the Screening and Day 1. The FVC at Week 26 will be the average of the highest FVC measurement recorded on two separate days at Week 26.

    Time frame: Baseline, Week 26

  2. Change From Baseline to Week 26 in Percent (%) Predicted FVC

    Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline to Week 26 in 6-Minute Walk Test (6MWT) Distance

    Baseline 6MWT distance will be the average of the measurements recorded at the Screening and Day 1 visits. The 6MWT distance at Week 26 will be defined as the average of the 6MWT distance recorded on two separate days at Week 26.

    Time frame: Baseline, Week 26

  2. Change From Baseline to Week 26 in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score

    The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Overall scores range from 0 to 1, with low scores representing a higher level of dysfunction.

    Time frame: Baseline, Week 26

  3. Change From Baseline to Week 26 in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score

    The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

    Time frame: Baseline, Week 26

  4. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Serious adverse event is any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, or resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect.

    Time frame: Up to Week 52

07

Results

Posted Nov 20, 2020

Participant flow

The study enrolled participants in Russia.

Participant flow — Overall Study
MilestonePirfenidone
Started60
Completed47
Not completed13
Withdrew: Death3
Withdrew: Withdrawal by subject3
Withdrew: Adverse event1
Withdrew: Lost to follow-up2
Withdrew: Physician decision3
Withdrew: Protocol violation1

Outcome measures

PrimaryChange From Baseline to Week 26 in Absolute Millilitre (mL) Forced Vital Capacity (FVC)

FVC is a standard pulmonary function test. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Baseline FVC will be the average of the highest FVC measurement recorded at the Screening and Day 1. The FVC at Week 26 will be the average of the highest FVC measurement recorded on two separate days at Week 26.

Time frame:
Baseline, Week 26
Reported as:
Mean · Milliliter (mL)
Change From Baseline to Week 26 in Absolute Millilitre (mL) Forced Vital Capacity (FVC)
Milliliter (mL)Pirfenidone
Change From Baseline to Week 26 in Absolute Millilitre (mL) Forced Vital Capacity (FVC)128.78 (-26.84 to 284.40)
PrimaryChange From Baseline to Week 26 in Percent (%) Predicted FVC

Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.

Time frame:
Baseline, Week 26
Reported as:
Mean · percent predicted
Change From Baseline to Week 26 in Percent (%) Predicted FVC
percent predictedPirfenidone
Change From Baseline to Week 26 in Percent (%) Predicted FVC-0.10 (-3.18 to 2.99)
SecondaryChange From Baseline to Week 26 in 6-Minute Walk Test (6MWT) Distance

Baseline 6MWT distance will be the average of the measurements recorded at the Screening and Day 1 visits. The 6MWT distance at Week 26 will be defined as the average of the 6MWT distance recorded on two separate days at Week 26.

Time frame:
Baseline, Week 26
Reported as:
Count of participants · Participants
Change From Baseline to Week 26 in 6-Minute Walk Test (6MWT) Distance
ParticipantsPirfenidone
Decline of >= 50 m14
Decline of <50 m to 0 m11
Improvement of >= 0 m24
SecondaryChange From Baseline to Week 26 in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score

The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Overall scores range from 0 to 1, with low scores representing a higher level of dysfunction.

Time frame:
Baseline, Week 26
Reported as:
Mean · score on scale
Change From Baseline to Week 26 in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score
score on scalePirfenidone
Change From Baseline to Week 26 in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score-0.0288 ± 0.1820
SecondaryChange From Baseline to Week 26 in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score

The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

Time frame:
Baseline, Week 26
Reported as:
Mean · score on scale
Change From Baseline to Week 26 in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score
score on scalePirfenidone
Change From Baseline to Week 26 in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score-0.6 ± 17.16
SecondaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Serious adverse event is any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, or resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
percentage of participantsPirfenidone
TEAEs81.7
TESAEs16.7

Adverse events

Collected over Up to 52 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirfenidone7/60 (11.7%)10/60 (16.7%)32/60 (53.3%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPirfenidone
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders2/60
DeathGeneral disorders2/60
Bronchitis chronicRespiratory, thoracic and mediastinal disorders1/60
DyspnoeaRespiratory, thoracic and mediastinal disorders1/60
Sudden cardiac deathGeneral disorders1/60
Atrial fibrillationCardiac disorders1/60
Atrial flutterCardiac disorders1/60
Bronchitis bacterialInfections and infestations1/60
Cholecystitis infectiveInfections and infestations1/60
PneumoniaInfections and infestations1/60
Most frequent other events
Most frequent other events
EventPirfenidone
NauseaGastrointestinal disorders16/60
Decreased appetiteMetabolism and nutrition disorders13/60
DyspepsiaGastrointestinal disorders8/60
VomitingGastrointestinal disorders8/60
DiarrhoeaGastrointestinal disorders7/60
DyspnoeaRespiratory, thoracic and mediastinal disorders6/60
CoughRespiratory, thoracic and mediastinal disorders4/60
Weight decreasedInvestigations4/60
PruritusSkin and subcutaneous tissue disorders4/60

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pirfenidone
Mean67.4 ± 7.75
Sex: Female, Male
Sex: Female, Male(Participants)Pirfenidone
Female19
Male41
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pirfenidone
Russian48
Tatar4
Bashkir4
Armenian1
Dagestani1
Kazah1
Uzbek1
08

Study locations

11 sites
  • Regional State Budgetary Institution of Healthcare "Regional Cinilcal Hospital"; Pulmonology
    Barnaul, Altaj 656024, Russian Federation
  • GBUZ Regional clinical hospital #4
    Chelyabinsk, Evenkija, Russian Federation
  • SBEI HPE "The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova"of MoH of RF
    Sankt-peterburg, Leningrad 197022, Russian Federation
  • Central NII tuberkuleza RAMN
    Moscow, Moskovskaja Oblast, Russian Federation
  • Pulmonologii NII FMBA of Russia
    Moscow, Moskovskaja Oblast, Russian Federation
  • New Hospital
    Yekaterinburg, Sverdlovsk, Russian Federation
  • I.M. Sechenov First Moscow State Medical University: The E.M. Tareyev Clinic
    Moscow, 119992, Russian Federation
  • Vladimirskiy Regional Scientific Research Inst.
    Moscow, 129110, Russian Federation
  • State Novosibirsk Regional Clinical Hospital
    Novosibirsk, 630087, Russian Federation
  • Republican clinical hospital named after G.G. Kuvatov
    UFA, 450005, Russian Federation
  • Budget Institution of Healthcare of Voronezh Region "Voronezh Regional Clinical Hospital #1"
    Voronezh, 394066, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — CT images of lungs, forced vital capacity (FVC) measurements, post-hoc analysis

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Nov 2019, 24 months.

Results were first posted in Nov 2020, 1 year after primary completion.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2017
First posted
Jul 6, 2017
StartActual
Oct 23, 2017
Primary completionActual
Nov 13, 2019
CompletionActual
Nov 13, 2019
Results first posted
Nov 20, 2020
Last update
Nov 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03208933
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 6, 2017
Start date
Oct 23, 2017
Primary completion
Nov 13, 2019
Completion
Nov 13, 2019
Results posted
Nov 20, 2020
Last update
Nov 20, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion